Intravenous administration of Compound 3, an ABZI-based compound, in the CT26 mouse model of colorectal cancer led to significant inhibition in tumor growth and improved overall survival, effects that were dependent on CD8+ T cell-mediated immune responses [111]. The gene discussed is CD8A; the disease is neoplasm.